Table 1.
Study characteristics
| Study | Location | Study type | No of women recruited (lost to follow-up) | Successful abortion RR (95% CI) | |
| Home based (H) | Clinic based (C) | ||||
| Akin et al 200424 | Turkey | NRS | 104 (4) | 104 (3) | 1.11 (0.98 to 1.25) |
| Alam et al 201325 | Bangladesh | NRS | 540 (20) | 111 (2) | 1.04 (.97 to 1.11) |
| Alam et al 201826 | Bangladesh | NRS | 1619 (2) | 125 (4) | 1.01 (0.97 to 1.04) |
| Bracken et al 200627 | Albania | NRS | 361 (5**) | 48 (1) | 0.99 (0.95 to 1.04) |
| Bracken 201028 | India | NRS | 530 (21) | 69 (3) | 0.96 (0.89 to 1.04) |
| Dagousset et al 200417 | France | NRS | 120 (0) | 289 (0) | 0.96 (0.92 to 1.00) |
| Elul et al 200135 | Vietnam | NRS | 106 (8) | 14 (0) | 1.22 (.93 to 1.61) |
| Elul et al 200135 | Tunisia | NRS | 170 (4) | 25 (0) | 1.06 (0.91 to 1.23) |
| Hajri et al 200429 | Tunisia | NRS | 252 (9) | 82 (0) | 1.04 (0.98 to 1.11) |
| Iyengar et al 201630 | India | NRS | 342 (not reported) | 389 (not reported) | 1.00 (0.96 to 1.04) |
| Karki et al 200931 | Nepal | NRS | 323 (31) | 77 (2) | 0.63 (0.30 to 1.34) |
| Li et al 201721 | China | RCT | 372 (2) | 372 (7) | 0.99 (0.97 to 1.01) |
| Ngoc et al 200432 | Vietnam | NRS | 1380 (24) | 174 (0) | 0.50 (0.26 to 0.98) |
| Okonufua et al 201436 | Nigeria | NRS | 159 (52) | 32 (7) | 0.97 (0.92 to 1.02) |
| Provansal et al 200916 | France | NRS | 143 (30) | 162 (64) | 0.91 (0.84 to 0.97) |
| Raghavan et al 201233 | Vietnam | NRS | 1933 (not reported) | 366 (not reported) | 1.02 (0.99 to 1.04) |
| Shrestha and Sedhai 201422 | Nepal | RCT | 94 (2) | 94 (2) | 1.02 (0.92 to 1.14) |
| Shuchita et al 200834 | India | NRS | 76 (1) | 23(1) | 0.99 (0.89 to 1.10) |
| Song et al 201823 | China | RCT | 283 (38) | 250 (29) | 0.99 (0.95 to 1.03 |
** Represents disaggregated loss-to follow-up (follow-up among both clinicand home users)
NRS, non-randomised studies; RCTs, randomised controlled trials; RR, risk ratio.